Rising Incidence of Diabetes in Children Amidst COVID-19: A Comprehensive Analysis

By HEOR Staff Writer

July 28, 2023

The COVID-19 pandemic has had far-reaching implications, with recent reports indicating a surge in the incidence of pediatric diabetes. To gain a clearer understanding of this association, a systematic review and meta-analysis of various studies published in English was conducted. 

The analysis included 42 studies, covering 102,984 incident diabetes cases. The results revealed a significant increase in the incidence rate of type 1 diabetes and diabetic ketoacidosis (DKA) in children and adolescents during the first two years of the pandemic compared to the pre-pandemic period. 

While the exact mechanism linking COVID-19 to the onset of diabetes remains unclear, potential factors might include lifestyle changes, stress, social isolation, and disruptions in healthcare access due to pandemic containment measures. 

These findings underscore the urgent need for increased resources and support for the growing number of children and adolescents with diabetes.  Future studies are required to determine whether this trend continues, and to shed light on the possible underlying mechanisms explaining these temporal changes. 

 

The increased incidence of DKA at diagnosis highlights the need to identify gaps in the pathway from the onset of diabetes symptoms to diagnosis. This information is crucial for developing effective strategies to prevent DKA at diagnosis in children. 

 

 

Reference url

Recent Posts

clinical trial monitoring
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

By HEOR Staff Writer

May 22, 2026

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decisi...
Novartis oncology advancements
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...
Baxfendy hypertension treatment
Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synthase Inhibitor
Baxfendy hypertension treatment received US Food and Drug Administration approval as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on other antihypertensive medications. AstraZeneca’s Baxfendy (baxdrostat) demonstrated statistically significant an...